Results 81 to 90 of about 1,198,346 (259)

THE EARLIEST EVIDENCE OF THE MANUFACTURING OF SOLUTIONS AND VISCOPLASTIC MIXTURES FROM PAINT PIGMENTS ON THE RUSSIAN PLAIN IN THE MIDDLE PALEOLITHIC

open access: yesНижневолжский археологический вестник
The article presents the results of studying a series of small individual pigment particles discovered in the cultural layer of the Chelyuskinets II site, which is part of the Lower Volga Middle Paleolithic group together with the Eurasian ...
Maria Zheltova   +12 more
doaj   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

open access: yesMolecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric   +10 more
wiley   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

open access: yesMolecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh   +12 more
wiley   +1 more source

Yakov A. Sher (1931–2019): Milestones of Academic Career

open access: yesСибСкрипт
Professor Yakov A. Sher (1931–2019), Doctor of History, was a world-famous specialist in prehistoric art. This research relied on the archives of the Institute for Material Culture History, the State Hermitage Museum, and the Kemerovo State University to
Lyudmila Yu. Kitova   +2 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Clan Crypts on the Lower Don of the Early Catacomb Time and Genesis Issues of the Catacomb Rite

open access: yesНижневолжский археологический вестник
The article provides comprehensive information about two Middle Bronze Age burials (No. 26, 42) from the kurgan 1 in the burial mound Vesely I near Novocherkassk in the Rostov region. The burials contained double tombs with a complex rite and prestigious
Alexey V. Kiyashko
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

CULTURAL, CHRONOLOGICAL AND SOCIAL ATTRIBUTION OF YAMNAYA AND CATACOMB BURIALS WITH METAL AXES IN THE DONETSK-DON REGION

open access: yesНижневолжский археологический вестник
In the first quarter of the 21st century, it became possible to expand research on the key issues of ancient metallurgy and metalworking, as well as related social and cultural processes, based on the database accumulated by Bronze Age archaeology ...
Aleksey Kiyashko
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy